Business Context and Reporting Period
This Form 8-K was filed by Aerpio Pharmaceuticals, Inc. (not Whitehawk Therapeutics, Inc.) on January 8, 2020. The registrant is a Delaware corporation with its principal executive offices in Cincinnati, Ohio. The company is classified as an emerging growth company and its common stock trades on the Nasdaq Capital Market under the symbol ARPO.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on a corporate event rather than financial performance data.
Material Changes and Events
Under Item 8.01 (Other Events), the company reported the issuance of a press release regarding clinical trial results for its product candidate, AKB-9778. Key details include:
- Product: Topical ocular formulation of AKB-9778.
- Indication: Primary Open Angle Glaucoma or Ocular Hypertension.
- Trial Phase: Phase 1b.
- Outcome: The formulation produced intraocular pressure (IOP) lowering with minimal hyperemia when combined with a prostaglandin.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, management commentary on future outlook, or specific risk factors beyond the standard disclosures inherent in clinical trial reporting. The primary focus is the positive clinical data point regarding the efficacy and tolerability of the drug candidate.
Investor Verification Checklist
- Verify the full text of the press release attached as Exhibit 99.1 for detailed statistical data on IOP lowering and hyperemia rates.
- Confirm the current status of the AKB-9778 development pipeline and subsequent trial plans.
- Review the company's most recent 10-K or 10-Q filings for actual financial metrics, as this 8-K does not contain them.
- Note the discrepancy in the request metadata: The filing is for Aerpio Pharmaceuticals, Inc., not Whitehawk Therapeutics, Inc.